标题/作者	年份
Side-effect management of chimeric antigen receptor (CAR) T-cell therapy ML Schubert, M Schmitt, L Wang, CA Ramos, K Jordan, C Müller-Tidow, ... Annals of oncology 32 (1), 34-48	2021
Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients F Marofi, HS Rahman, ZMJ Al-Obaidi, AT Jalil, WK Abdelbasset, ... Stem Cell Research & Therapy 12 (1), 1-23	2021
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events MV Maus, S Alexander, MR Bishop, JN Brudno, C Callahan, ML Davila, ... Journal for immunotherapy of cancer 8 (2)	2020
Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies T Jain, A Knezevic, M Pennisi, Y Chen, JD Ruiz, TJ Purdon, SM Devlin, ... Blood advances 4 (15), 3776-3787	2020
Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma JM Logue, E Zucchetti, CA Bachmeier, GS Krivenko, V Larson, D Ninh, ... Haematologica 106 (4), 978	2021
Use of chimeric antigen receptor T cell therapy in clinical practice for relapsed/refractory aggressive B cell non-Hodgkin lymphoma: an expert panel opinion from the American Society for Transplantation and Cellular Therapy T Jain, M Bar, AJ Kansagra, EA Chong, SK Hashmi, SS Neelapu, M Byrne, ... Biology of Blood and Marrow Transplantation 25 (12), 2305-2321	2019
Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma K Wudhikarn, ML Palomba, M Pennisi, M Garcia-Recio, JR Flynn, ... Blood cancer journal 10 (8), 79	2020
Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: first-in-human, phase I trial J Pan, Y Tan, G Wang, B Deng, Z Ling, W Song, S Seery, Y Zhang, ... Journal of Clinical Oncology 39 (30), 3340-3351	2021
CAR-HEMATOTOX: A model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma K Rejeski, A Perez, P Sesques, E Hoster, C Berger, L Jentzsch, ... Blood, The Journal of the American Society of Hematology 138 (24), 2499-2513	2021
Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA) PJ Hayden, C Roddie, P Bader, GW Basak, H Bonig, C Bonini, ... Annals of Oncology 33 (3), 259-275	2022
The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma J Wei, Y Liu, C Wang, Y Zhang, C Tong, G Dai, W Wang, JEJ Rasko, ... Signal Transduction and Targeted Therapy 5 (1), 134	2020
Management of immunotherapy-related toxicities, version 1.2022, NCCN clinical practice guidelines in oncology JA Thompson, BJ Schneider, J Brahmer, A Achufusi, P Armand, ... Journal of the National Comprehensive Cancer Network 20 (4), 387-405	2022
Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma P Strati, A Varma, S Adkins, LJ Nastoupil, JR Westin, FB Hagemeister, ... Haematologica 106 (10), 2667	2021
Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma JH Baird, DJ Epstein, JS Tamaresis, Z Ehlinger, JY Spiegel, J Craig, ... Blood advances 5 (1), 143-155	2021
Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy (PCTT) GR Nahas, KV Komanduri, D Pereira, M Goodman, AM Jimenez, ... Leukemia & lymphoma 61 (4), 940-943	2020
Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies CW Freyer, DL Porter Journal of Allergy and Clinical Immunology 146 (5), 940-948	2020
GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany WA Bethge, P Martus, M Schmitt, U Holtick, M Subklewe, B von Tresckow, ... Blood, The Journal of the American Society of Hematology 140 (4), 349-358	2022
Invasive mold infections after chimeric antigen receptor–modified T-cell therapy: a case series, review of the literature, and implications for prophylaxis G Haidar, K Dorritie, R Farah, T Bogdanovich, MH Nguyen, P Samanta Clinical Infectious Diseases 71 (3), 672-676	2020
Genetic engineering of T cells for immunotherapy GI Ellis, NC Sheppard, JL Riley Nature Reviews Genetics 22 (7), 427-447	2021
Cellular therapy: Immune‐related complications JH Oved, DM Barrett, DT Teachey Immunological reviews 290 (1), 114-126	2019

1 - 20

计算机程序会自动估算并确定日期和引用次数。